August 17–19, 2020 | 10:00AM EDT | 2:00PM UTC | 4:00PM CEST*
*Program is subject to change
The live portion of this conference has concluded and all presentations are now available for purchase on demand. Registrants to the live event may access this content anytime for up to 9 months following the event.
Keystone Symposia welcomes the global scientific community and aims to connect researchers within and across disciplines to accelerate the advancement of biomedical and life sciences. This form may be used for scientists from low- and middle-income countries of all career stages to determine eligibility and request free access to scientific content presented during recent eSymposia events. If eligible, you will be sent an access code for the On Demand content of the eSymposia event(s) of interest.
Cancer immunotherapy provides unprecedented long-term antitumor activity in some patients, however the majority of patients with advanced cancers only experience short-term remission. To achieve better outcomes for everyone will require a mechanistic understanding of response, and resistance, to these therapies, including immune inhibitory checkpoint blockade and T-cell engineering. These insights will provide rationale for how to best combine these therapeutic approaches for sustained clinical success.
In this virtual meeting we will tackle many of these unanswered questions in the field, including:
The program highlights novel methodologies, data-analysis techniques, and tools to integrate high throughput and patient-derived sample data, revealing powerful new approaches to understand both genetic and adaptive resistance mechanisms, and ways to overcome them. The largest human experiment to date is currently underway, testing over 1,000 agents and combinations; examining preliminary results will be key to refining our approaches, and understanding of immunity in patients with cancer.
Overall, participants will gain a more comprehensive understanding of tumor immunology, and how to leverage this knowledge to outsmart tumors and achieve lasting remission in patients. In addition, the virtual event provides a platform for trainees, junior researchers, and rising stars in the field to share promising new directions that will progress the field forward, towards new and innovative breakthroughs.
Keystone Symposia conferences provide unique opportunities for trainees and junior researchers to present their work to global audiences and field leaders. The eSymposia platform continues this strong tradition of providing these critical career-development and advancement experiences for the next-generation, incorporating short talks and ePoster sessions to highlight rising stars in the field.
Submit your work to be featured in an ePoster session alongside world leaders!
Registration for this meeting is now closed.
Abstract Submission: Passed
James P. Allison
University of Texas MD Anderson Cancer Center
Immune Checkpoint Blockade in Cancer Therapy:
New Insights into Therapeutic Mechanisms
Editors Attending This Meeting
Speaking at this eSymposia
Massachusetts Institute of Technology
University of California, Los Angeles
Yvonne Y. Chen
University of California, Los Angeles
University of Washington
Novartis Institutes for BioMedical Research
Nadine A. Defranoux
Parker Institute for Cancer Immunotherapy
James R. Heath
Institute for Systems Biology
Funding for this conference was made possible (in part) by 1R13CA246936-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
The views expressed in this eSymposia are those of the participants and not necessarily of the participants’ organizations or of Keystone Symposia.
Explore all cancer-related meetings on the Keystone Symposia website.